share_log

Recursion Pharmaceuticals | 4: Statement of changes in beneficial ownership of securities-Director Borgeson Blake

Recursion Pharmaceuticals | 4: Statement of changes in beneficial ownership of securities-Director Borgeson Blake

Recursion Pharmaceuticals | 4:持股变动声明-董事 Borgeson Blake
美股SEC公告 ·  06/27 19:18
Moomoo AI 已提取核心信息
Blake Borgeson, a reporting person associated with Recursion Pharmaceuticals, Inc. [RXRX], completed a sale of 11,447 shares of Class A Common Stock on June 25, 2024. The transaction was executed in the open market at a price of $9.5052 per share, resulting in a total sale value of approximately $108,806. Following the sale, Borgeson directly holds a total of 7,177,116 shares in the company. The sale reflects a direct ownership transaction and was completed as an open market or private sale.
Blake Borgeson, a reporting person associated with Recursion Pharmaceuticals, Inc. [RXRX], completed a sale of 11,447 shares of Class A Common Stock on June 25, 2024. The transaction was executed in the open market at a price of $9.5052 per share, resulting in a total sale value of approximately $108,806. Following the sale, Borgeson directly holds a total of 7,177,116 shares in the company. The sale reflects a direct ownership transaction and was completed as an open market or private sale.
Blake Borgeson是与Recursion Pharmaceuticals有关的报告人[RXRX],于2024年6月25日完成了销售11,447股A类普通股的交易。交易在开放市场以每股9.5052美元的价格执行,结果产生了总销售价值约为108,806美元。在此次交易后,Borgeson直接持有公司7177116股的总数。该销售反映了一项直接所有权交易,并作为开放市场或私人销售完成。
Blake Borgeson是与Recursion Pharmaceuticals有关的报告人[RXRX],于2024年6月25日完成了销售11,447股A类普通股的交易。交易在开放市场以每股9.5052美元的价格执行,结果产生了总销售价值约为108,806美元。在此次交易后,Borgeson直接持有公司7177116股的总数。该销售反映了一项直接所有权交易,并作为开放市场或私人销售完成。
声明:本内容仅用作提供资讯及教育之目的,不构成对任何特定投资或投资策略的推荐或认可。 更多信息